Ionis publishes ZANVASTRO FDA approval presentation for Alexander disease treatment

• Ionis published slides outlining FDA clearance of ZANVASTRO (zilganersen) for pediatric, adult Alexander disease patients.
• Material launch catalyst for Ionis’ first independently commercialized neurology medicine in the U.S.
• Pivotal trial met its primary endpoint in patients aged 5 or older, stabilizing 10-meter walk test gait speed at Week 61 (p=0.041).
• Secondary measures supported efficacy, including GMFM-88 improvement in ages 2-4 (nominal p=0.034) plus plasma GFAP reduction (nominal p=0.003).
• Safety profile described as generally mild-to-moderate; one aseptic meningitis serious event resolved without discontinuation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.